中国批准 " Aizhida " ,这是针对6岁及6岁以上的儿童和青少年的一种新的每日使用一次的ADHD药物。 China approves Aizhida, a new once-daily ADHD drug, for children and teens aged 6 and older.

中国批准了Aizhida,这是上海方舟生物药剂公司为6岁及6岁以上的病人开发的一种新的自上海方舟生物药剂DADHD新药。 China has approved Aizhida, a new once-daily ADHD medication developed by Shanghai Ark Biopharmaceutical, for patients aged 6 and older. 该药物结合了即期和延长释放成分,以提供迅速的症状缓解和全日覆盖,成为中国首例此类药物。 The drug combines immediate- and extended-release components to provide rapid symptom relief and full-day coverage, making it the first of its kind in China. 根据积极的第三阶段试验结果核准,它解决了未满足的需要,其状况估计影响中国儿童和青少年的6.4%。 Approved based on positive Phase III trial results, it addresses unmet needs in a condition affecting an estimated 6.4% of Chinese children and adolescents. 在美国已经批准的药物有望改善治疗结果。 The medication, already approved in the U.S., is expected to improve treatment outcomes.